440 related articles for article (PubMed ID: 26075320)
1. Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure.
Ogawa E; Furusyo N; Dohmen K; Kajiwara E; Kawano A; Nomura H; Takahashi K; Satoh T; Azuma K; Nakamuta M; Koyanagi T; Kotoh K; Shimoda S; Hayashi J;
J Viral Hepat; 2015 Dec; 22(12):992-1001. PubMed ID: 26075320
[TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness and safety study of triple therapy with simeprevir or telaprevir for non-cirrhotic patients with chronic hepatitis C virus genotype 1b infection.
Ogawa E; Furusyo N; Kajiwara E; Nomura H; Kawano A; Takahashi K; Dohmen K; Satoh T; Azuma K; Nakamuta M; Koyanagi T; Kotoh K; Shimoda S; Hayashi J
J Gastroenterol Hepatol; 2015 Dec; 30(12):1759-67. PubMed ID: 26095167
[TBL] [Abstract][Full Text] [Related]
3. Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial.
Reddy KR; Zeuzem S; Zoulim F; Weiland O; Horban A; Stanciu C; Villamil FG; Andreone P; George J; Dammers E; Fu M; Kurland D; Lenz O; Ouwerkerk-Mahadevan S; Verbinnen T; Scott J; Jessner W
Lancet Infect Dis; 2015 Jan; 15(1):27-35. PubMed ID: 25482330
[TBL] [Abstract][Full Text] [Related]
4. Mutational diversity of NS5A and NS3 during triple therapy (telaprevir, pegylated-interferon-α 2b and ribavirin) for genotype 1b chronic hepatitis C: The Kobe Hepatitis Therapeutic Group.
Bai F; Yano Y; Kim SR; Seo Y; Miki A; Saito M; Hirano H; Momose K; Minami A; Hatazawa Y; Hayakumo T; Widasari DI; Rinonce HT; Sugano M; Tani S; Yoon S; Imoto S; Azuma T; Hotta H; Hayashi Y
Int J Mol Med; 2014 Jun; 33(6):1652-6. PubMed ID: 24647743
[TBL] [Abstract][Full Text] [Related]
5. Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study.
Dieterich D; Rockstroh JK; Orkin C; Gutiérrez F; Klein MB; Reynes J; Shukla U; Jenkins A; Lenz O; Ouwerkerk-Mahadevan S; Peeters M; De La Rosa G; Tambuyzer L; Jessner W
Clin Infect Dis; 2014 Dec; 59(11):1579-87. PubMed ID: 25192745
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.
Hézode C; Fontaine H; Dorival C; Zoulim F; Larrey D; Canva V; De Ledinghen V; Poynard T; Samuel D; Bourliere M; Alric L; Raabe JJ; Zarski JP; Marcellin P; Riachi G; Bernard PH; Loustaud-Ratti V; Chazouilleres O; Abergel A; Guyader D; Metivier S; Tran A; Di Martino V; Causse X; Dao T; Lucidarme D; Portal I; Cacoub P; Gournay J; Grando-Lemaire V; Hillon P; Attali P; Fontanges T; Rosa I; Petrov-Sanchez V; Barthe Y; Pawlotsky JM; Pol S; Carrat F; Bronowicki JP;
Gastroenterology; 2014 Jul; 147(1):132-142.e4. PubMed ID: 24704719
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Daclatasvir and Asunaprevir for Chronic HCV 1b Infection with Telaprevir and Simeprevir plus Peginterferon and Ribavirin, with a Focus on the Prevention of Occurrence and Recurrence of Hepatocellular Carcinoma.
Sugimoto K; Kim SR; Kim SK; Imoto S; Tohyama M; Kim KI; Ohtani A; Hatae T; Yano Y; Kudo M; Hayashi Y
Oncology; 2015; 89 Suppl 2():42-6. PubMed ID: 26584035
[TBL] [Abstract][Full Text] [Related]
8. Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study.
Gane EJ; DeJesus E; Janczewska E; George J; Diago M; Da Silva MH; Reesink H; Nikitin I; Hinrichsen H; Bourgeois S; Ferenci P; Shukla U; Kalmeijer R; Lenz O; Fevery B; Corbett C; Beumont M; Jessner W
BMC Infect Dis; 2017 Jun; 17(1):389. PubMed ID: 28577353
[TBL] [Abstract][Full Text] [Related]
9. Emergence of telaprevir-resistant variants detected by ultra-deep sequencing after triple therapy in patients infected with HCV genotype 1.
Akuta N; Suzuki F; Seko Y; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Hara T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
J Med Virol; 2013 Jun; 85(6):1028-36. PubMed ID: 23588728
[TBL] [Abstract][Full Text] [Related]
10. Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimen - The ANRS CO20-CUPIC study.
Bailly F; Virlogeux V; Dufour C; Pradat P; Hézode C; Larrey D; Alric L; Samuel D; Bourlière M; Métivier S; Zarski JP; Fontaine H; Loustaud-Ratti V; Serfaty L; Bronowicki JP; Carrat F; Zoulim F;
Clin Res Hepatol Gastroenterol; 2015 Sep; 39(4):443-50. PubMed ID: 25636238
[TBL] [Abstract][Full Text] [Related]
11. Favourable SVR12 rates with boceprevir or telaprevir triple therapy in HIV/HCV coinfected patients.
Arends JE; van der Meer JT; Posthouwer D; Kortmann W; Brinkman K; van Assen S; Smit C; van der Valk M; van der Ende M; Schinkel J; Reiss P; Richter C; Hoepelman AI; ;
Neth J Med; 2015 Aug; 73(7):324-30. PubMed ID: 26314715
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Tolerability of Pegylated Interferon and Ribavirin in Combination with Simeprevir to Treat Hepatitis C Virus Infections After Living Donor Liver Transplantation.
Miuma S; Ichikawa T; Miyaaki H; Haraguchi M; Tamada Y; Shibata H; Taura N; Soyama A; Hidaka M; Takatsuki M; Eguchi S; Nakao K
J Interferon Cytokine Res; 2016 Jun; 36(6):358-66. PubMed ID: 27243278
[TBL] [Abstract][Full Text] [Related]
13. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
Jacobson IM; Dore GJ; Foster GR; Fried MW; Radu M; Rafalsky VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Scott J; Sinha R; Beumont-Mauviel M
Lancet; 2014 Aug; 384(9941):403-13. PubMed ID: 24907225
[TBL] [Abstract][Full Text] [Related]
14. The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis.
Pearlman BL; Ehleben C; Perrys M
Gastroenterology; 2015 Apr; 148(4):762-70.e2; quiz e11-2. PubMed ID: 25557952
[TBL] [Abstract][Full Text] [Related]
15. Simeprevir plus peginterferon/ribavirin for HCV genotype 1-infected treatment-naïve patients in China and South Korea.
Wei L; Han T; Yang D; Heo J; Shang J; Cheng J; Chen X; Xie Q; Kim JH; Kalmeijer R; Ouwerkerk-Mahadevan S; Hoeben E; Lenz O; Verbinnen T; Sinha R; Li M; Scott J; Peeters M; Witek J;
J Gastroenterol Hepatol; 2016 May; 31(5):912-20. PubMed ID: 26777137
[TBL] [Abstract][Full Text] [Related]
16. Use of simeprevir following pre-emptive pegylated interferon/ribavirin treatment for recurrent hepatitis C in living donor liver transplant recipients: a 12-week pilot study.
Tanaka T; Sugawara Y; Akamatsu N; Kaneko J; Tamura S; Aoki T; Sakamoto Y; Hasegawa K; Kurosaki M; Izumi N; Kokudo N
J Hepatobiliary Pancreat Sci; 2015 Feb; 22(2):144-50. PubMed ID: 25338946
[TBL] [Abstract][Full Text] [Related]
17. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.
Furusyo N; Ogawa E; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J;
J Hepatol; 2013 Aug; 59(2):205-12. PubMed ID: 23542346
[TBL] [Abstract][Full Text] [Related]
18. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial.
Forns X; Lawitz E; Zeuzem S; Gane E; Bronowicki JP; Andreone P; Horban A; Brown A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; Scott J; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M
Gastroenterology; 2014 Jun; 146(7):1669-79.e3. PubMed ID: 24602923
[TBL] [Abstract][Full Text] [Related]
19. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin.
Akuta N; Suzuki F; Hirakawa M; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Chayama K; Nakamura Y; Kumada H
Hepatology; 2010 Aug; 52(2):421-9. PubMed ID: 20648473
[TBL] [Abstract][Full Text] [Related]
20. Early Viral Response Predicts the Efficacy of Antiviral Triple Therapy with Simeprevir, Peg-Interferon and Ribavirin in Patients Infected with Hepatitis C Virus Genotype 1.
Nishida N; Iwanishi M; Minami T; Chishina H; Arizumi T; Takita M; Kitai S; Yada N; Ida H; Hagiwara S; Minami Y; Ueshima K; Sakurai T; Kitano M; Kudo M
Dig Dis; 2015 Oct; 33(6):708-14. PubMed ID: 26488400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
